Comprehensive genomic profiling (CGP) is revolutionizing precision oncology by identifying a broad range of actionable alterations in non-small cell lung cancer (NSCLC), including complex signatures like TMB and HRD. In tissue-limited or time-sensitive cases, a staged testing strategy is critical. This workshop highlights findings from the DelPHI 2.0 collaboration between Protean BioDiagnostics and Roche Diagnostics that evaluated integrating digital PCR (dPCR), Immunohistochemistry (IHC), and CGP workflows. Centered on CGP, this multimodal approach uses rapid dPCR and IHC to quickly detect key driver mutations and protein biomarkers—enhancing efficiency while conserving CGP’s full analytical capacity. Data from an NSCLC cohort demonstrate how this strategy shortens turnaround, reduces costs, and applies CGP where it adds the greatest value, delivering comprehensive insights.
